New York, Jan 26, 2026, 05:31 ET — Premarket
- Sarepta shares jump in early premarket, extending gains from late Friday after-hours trading
- Monday’s update on Elevidys’ long-term trial results has investors closely watching.
- Durability and monitoring stay key, driven by safety standards and label limits
Sarepta Therapeutics (SRPT.O) climbed about 6.5% to $22.51 in early Monday action. The stock stayed tight, swinging just between $22.51 and $22.57, with roughly 17,600 shares traded, per Public.com data. 1
The stock surged 9.65% to $23.17 in after-hours trading Friday, fueled by investor bets ahead of Sarepta’s update on its Duchenne muscular dystrophy gene therapy, RTTNews reported. Sarepta plans to unveil three-year “topline” functional data from Part 1 of EMBARK, its global, randomized, placebo-controlled Phase 3 trial of Elevidys in ambulatory kids aged four to seven at treatment, the report added. 2
Why it matters now: Sarepta is under pressure to produce long-term functional data to convince doctors, regulators, and payers that Elevidys remains effective beyond initial outcomes. The stock has already factored in skepticism about its durability.
“Topline” results provide a quick look at the main outcomes. Investors often treat them as a rough guide, waiting for the detailed tables, subgroup breakdowns, and safety information before making decisions.
Cambridge-based biotech Sarepta focuses on genetic therapies targeting rare diseases. Duchenne muscular dystrophy stands out as its primary area of research, the company’s website confirms. 3
Elevidys faces major safety red flags. In November, the U.S. Food and Drug Administration slapped on a boxed warning, restricting the treatment to ambulatory patients aged four and up. This came after two non-ambulatory pediatric patients died from acute liver failure, Reuters reported. A Parent Project Muscular Dystrophy spokesperson said the update underscores that “serious questions remain” about the therapy’s safety and its long-term impact. 4
Sarepta’s shares have been volatile following trial news. In early November, the company announced that a late-stage study for two other Duchenne drugs missed its primary endpoint, triggering a more than 37% drop in after-hours trading. J.P. Morgan analyst Anupam Rama warned that “regulatory processes can be a wild card,” according to 6 .
Traders will focus Monday on the three-year functional trend lines, scrutinizing their alignment and consistency across patients. They’ll also be alert for any fresh details the company might provide about monitoring or practical applications.
This setup frequently sparks sharp swings both ways. Pre-market trading often magnifies the initial reaction, especially around binary biotech events.
The risk is straightforward: if the update indicates reduced benefits, greater variability, or fresh safety issues, early gains could vanish quickly and regulatory battles might flare up again.
The company’s webcast and conference call kick off at 8:30 a.m. ET on Monday. Investors will watch closely to see if Sarepta’s premarket gains hold steady when the market opens. 5
